BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 10606947)

  • 21. [Necrolytic migratory erythema revealing glucagonoma without diabetes].
    Marty C; Bennet A; Bayle P; Danjoux M; Lalande T; Marguery MC; Bazex J
    Ann Med Interne (Paris); 2003 Dec; 154(8):552-6. PubMed ID: 15037834
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Rare presentation of endocrine pancreatic tumour: a case of glucagonoma without necrolytic migratory erythema?
    Manes G; Pellegrini A; Riccardi F; Uomo G
    Ital J Gastroenterol; 1995 Jun; 27(5):248-9. PubMed ID: 8541575
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Iatrogenic necrolytic migratory erythema: a case report and review of nonglucagonoma-associated necrolytic migratory erythema.
    Mullans EA; Cohen PR
    J Am Acad Dermatol; 1998 May; 38(5 Pt 2):866-73. PubMed ID: 9591806
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Necrolytic migratory erythema and pancreatic glucagonoma.
    Rodríguez G; Vargas E; Abaúnza C; Cáceres S
    Biomedica; 2016 Jun; 36(2):176-81. PubMed ID: 27622478
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The glucagonoma syndrome. Clinical and pathologic features in 21 patients.
    Wermers RA; Fatourechi V; Wynne AG; Kvols LK; Lloyd RV
    Medicine (Baltimore); 1996 Mar; 75(2):53-63. PubMed ID: 8606627
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dermatitis, glossitis, stomatitis, cheilitis, anemia and weight loss: a classic presentation of pancreatic glucagonoma.
    Povoski SP; Zaman SA; Ducatman BS; McFadden DW
    W V Med J; 2002; 98(1):12-4. PubMed ID: 11941895
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Necrolytic migratory erythema: A diagnostic clue in glucagonoma syndrome.
    Moreno-Suárez F; Pulpillo-Ruiz Á; Fontillón Alberdi M
    Med Clin (Barc); 2017 Apr; 148(8):e45. PubMed ID: 27567335
    [No Abstract]   [Full Text] [Related]  

  • 28. Necrolytic migratory erythema, presenting as candidiasis, due to a pancreatic glucagonoma.
    Katz R; Fischmann AB; Galotto J; Guccio JG; Higgins GA; Ortega LG; West WH; Recant L
    Cancer; 1979 Aug; 44(2):558-63. PubMed ID: 476569
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Necrolytic Migratory Erythema: Complete Healing after Surgical Removal of Pancreatic Carcinoma.
    V'lckova-Laskoska M; Balabanova-Stefanova M; Arsovska-Bezhoska I; Caca-Biljanovska N; Laskoski D
    Acta Dermatovenerol Croat; 2018 Dec; 26(4):329-332. PubMed ID: 30665484
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Apoptosis with positive direct immunofluorescence findings in a patient with necrolytic migratory erythema.
    Perniciaro C; Rappaport KD; White JW
    Cutis; 1998 Sep; 62(3):129-32. PubMed ID: 9770127
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Necrolytic migratory erythema: an important sign of glucagonoma.
    Cui M; Wang R; Liao Q
    Postgrad Med J; 2021 Mar; 97(1145):199. PubMed ID: 32527759
    [No Abstract]   [Full Text] [Related]  

  • 32. Cutaneous and oral changes as the only manifestations of the glucagonoma syndrome.
    Ditty JF; Lang PG
    South Med J; 1982 Feb; 75(2):222-4. PubMed ID: 6277014
    [No Abstract]   [Full Text] [Related]  

  • 33. [Necrolytic migratory erythema in glucagonoma syndrome (author's transl)].
    Kitoh M; Ohyama K; Shigeo ; Arao AT
    Nihon Hifuka Gakkai Zasshi; 1981 Apr; 91(5):559-68. PubMed ID: 6270429
    [No Abstract]   [Full Text] [Related]  

  • 34. [66-year-old patient with necrolytic migratory erythema, weight loss, anemia and diabetes mellitus].
    Michels G; Rasokat H; Nierhoff D; Steffen HM
    Dtsch Med Wochenschr; 2010 Aug; 135(33):1601-2. PubMed ID: 20717864
    [No Abstract]   [Full Text] [Related]  

  • 35. Glucagonoma and the glucagonoma syndrome - cumulative experience with an elusive endocrine tumour.
    Eldor R; Glaser B; Fraenkel M; Doviner V; Salmon A; Gross DJ
    Clin Endocrinol (Oxf); 2011 May; 74(5):593-8. PubMed ID: 21470282
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Glucagonoma syndrome without diabetes mellitus].
    Mikkelsen CS; Mikkelsen DB; Vestergaard V; Clemmensen O; Nielsen HO; Bygum A
    Ugeskr Laeger; 2008 Nov; 170(47):3876. PubMed ID: 19014744
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Necrolytic migratory erythema, first symptom of a malignant glucagonoma: treatment by long-acting somatostatin and surgical resection. Report of three cases.
    El Rassi Z; Partensky C; Valette PJ; Berger F; Chayvialle JA
    Eur J Surg Oncol; 1998 Dec; 24(6):562-7. PubMed ID: 9870735
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The glucagonoma syndrome: a review of its features and discussion of new perspectives.
    Chastain MA
    Am J Med Sci; 2001 May; 321(5):306-20. PubMed ID: 11370794
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Glucagon cell adenomatosis: a new entity associated with necrolytic migratory erythema and glucagonoma syndrome.
    Otto AI; Marschalko M; Zalatnai A; Toth M; Kovacs J; Harsing J; Tulassay Z; Karpati S
    J Am Acad Dermatol; 2011 Aug; 65(2):458-459. PubMed ID: 21763589
    [No Abstract]   [Full Text] [Related]  

  • 40. Delayed diagnosis of glucagonoma syndrome: a case report.
    Huo J; Liu P; Chen X; Wu J; An J; Ren J
    Int J Dermatol; 2016 Nov; 55(11):1272-1274. PubMed ID: 26679842
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.